Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed this Form 8-K on June 9, 2021, reporting results of its 2021 annual meeting of stockholders held that day. The filing concerns corporate governance and auditor ratification rather than operating or financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Material Changes Versus the Prior Comparable Period
No comparable-period financial information or material operating changes are disclosed. Stockholders elected three directors and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Governance, Outlook, and Other Matters
- Johan Christenson, M.D., Ph.D. and Fouad Namouni, M.D. were elected as Class II directors, each to serve until the 2024 annual meeting and until a successor is elected and qualified.
- Richard Peters, M.D., Ph.D. was elected as a Class I director for the remainder of a term expiring at the 2023 annual meeting and until a successor is elected and qualified.
- Ernst & Young LLP’s appointment was ratified for the fiscal year ending December 31, 2021.
- The filing provides no new guidance, outlook, management commentary, contingencies, or unusual financial items.
Vote Results
| Proposal | For | Against or Withheld | Abstaining | Broker Non-Votes |
|---|---|---|---|---|
| Johan Christenson election | 9,203,832 | 415,468 withheld | Not separately stated | 4,149,014 |
| Fouad Namouni election | 8,621,227 | 998,073 withheld | Not separately stated | 4,149,014 |
| Richard Peters election | 9,207,831 | 411,469 withheld | Not separately stated | 4,149,014 |
| Ernst & Young ratification | 13,696,463 | 52,540 | 19,311 | Not stated |
Key Facts to Verify
- Confirm the elected directors’ committee assignments, independence status, and applicable term details in subsequent filings.
- Review the company’s proxy statement filed April 28, 2021 for background on the proposals and nominees.
- Review subsequent periodic filings for the company’s financial condition, liquidity, clinical development status, and any changes in auditor or governance.